Administration of rituximab during the first trimester of pregnancy without consequences for the newborn.
Fiche publication
Date publication
avril 2006
Journal
Journal of perinatology : official journal of the California Perinatal Association
Auteurs
Membres identifiés du Cancéropôle Est :
Dr OJEDA-URIBE Mario, Dr DRENOU Bernard
Tous les auteurs :
Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A
Lien Pubmed
Résumé
Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.
Mots clés
Adrenal Cortex Hormones, administration & dosage, Adult, Anemia, Hemolytic, Autoimmune, drug therapy, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, administration & dosage, Drug Therapy, Combination, Erythrocyte Transfusion, Female, Humans, Infant, Newborn, Pregnancy, Pregnancy Complications, Hematologic, drug therapy, Pregnancy Outcome, Pregnancy Trimester, First, Recurrence, Rituximab, Treatment Refusal
Référence
J Perinatol. 2006 Apr;26(4):252-5